NAU
Navsari, India
NAU
Navsari, India

Time filter

Source Type

PHOENIX, Feb. 28, 2017 (GLOBE NEWSWIRE) -- A new test for Lyme Disease may prove to be the most accurate tool available for the difficult-to-diagnose disease, giving hope to thousands of undiagnosed and misdiagnosed patients, if funding can be found to move it through clinical study to production. The test, called LymeSeq™ is poised to transform the speed and precision of diagnosis over current tests. This test will detect multiple strains of Lyme bacteria, plus all major co-infections and non-Lyme causes of disease like Influenza and Staph. LymeSeq, developed by research scientists at Translational Genomics Research Institute (TGen), has been funded by Focus On Lyme. The test may represent a breakthrough in diagnosis and testing for Lyme disease, which are currently about 50 percent accurate. After five years shuttling her daughter specialists across the country and intense antibiotic treatments to battle this disease, Focus On Lyme Executive Director Tammy Crawford got in touch with TGen. Knowing the institute’s experience using genetic sequencing to identify pathogens like tuberculosis and E. coli, Crawford asked if TGen could do the same for Lyme disease and when they said yes, she personally funded the initial research.  The researchers are led by Dr. Paul Keim, the Executive Director of the Pathogen and Microbiome Institute and the Cowden Endowed Chair of Microbiology at Northern Arizona University (NAU), as well as Director of the Pathogen Genomics Division TGen North in Flagstaff, Ariz. Dr. Keim is an internationally recognized expert in DNA-based research methods, a fellow of the American Academy of Microbiology, and a fellow of the American Association for the Advancement of Science. LymeSeq works by targeting and amplifying specific regions of the Lyme bacteria’s DNA as well as specific genes in related bacteria. That amplified DNA gets sequenced, then researchers determine the bacterial species present in the sample by searching for the DNA code specific to Lyme or other bacteria, explained Dr. David Engelthaler, Director of Programs and Operations at TGen North, and Director of the Public Health and Translational Genomics Center at the Pathogen and Microbiome Institute. “LymeSeq has the potential to transform emergency rooms and doctor’s offices world wide, said Holly Ahern, MS, MT (ASCP) and SUNY Adirondack associate professor of microbiology, and a member of the leadership team at Focus on Lyme. Dr. Richard Horowitz, author of "How Can I Get Better? An Action Plan for Treating Resistant Lyme and Chronic Disease,” said, “more than ever, we need an accurate test” referencing the National Science Foundation’s identification of Lyme disease as an emerging pandemic threat, siting the current “problematic two-tiered testing scheme,” for which LymeSeq shows promise of being “superior in every way.” With exciting early signs of high accuracy, the next step is to advance the test into human trials. Crawford’s team of volunteers has raised more than $301,730 towards a goal of $500,000 to bring the test to market. BHHS Legacy Foundation recently stepped forward with an additional $100,000 in grant funding. “With the development of any new medical advancement, the steps are long, arduous and expensive. But we’ve come so far in such a short period of time, we need your help to get us to the finish line,” Crawford said. “We are all volunteers. Every single penny we raise goes towards the research, we keep nothing back.” For more information visit www.focusonlyme.org. To donate, visit: www.focusonlyme.org/donate.


PHOENIX, Feb. 28, 2017 (GLOBE NEWSWIRE) -- A new test for Lyme Disease may prove to be the most accurate tool available for the difficult-to-diagnose disease, giving hope to thousands of undiagnosed and misdiagnosed patients, if funding can be found to move it through clinical study to production. The test, called LymeSeq™ is poised to transform the speed and precision of diagnosis over current tests. This test will detect multiple strains of Lyme bacteria, plus all major co-infections and non-Lyme causes of disease like Influenza and Staph. LymeSeq, developed by research scientists at Translational Genomics Research Institute (TGen), has been funded by Focus On Lyme. The test may represent a breakthrough in diagnosis and testing for Lyme disease, which are currently about 50 percent accurate. After five years shuttling her daughter specialists across the country and intense antibiotic treatments to battle this disease, Focus On Lyme Executive Director Tammy Crawford got in touch with TGen. Knowing the institute’s experience using genetic sequencing to identify pathogens like tuberculosis and E. coli, Crawford asked if TGen could do the same for Lyme disease and when they said yes, she personally funded the initial research.  The researchers are led by Dr. Paul Keim, the Executive Director of the Pathogen and Microbiome Institute and the Cowden Endowed Chair of Microbiology at Northern Arizona University (NAU), as well as Director of the Pathogen Genomics Division TGen North in Flagstaff, Ariz. Dr. Keim is an internationally recognized expert in DNA-based research methods, a fellow of the American Academy of Microbiology, and a fellow of the American Association for the Advancement of Science. LymeSeq works by targeting and amplifying specific regions of the Lyme bacteria’s DNA as well as specific genes in related bacteria. That amplified DNA gets sequenced, then researchers determine the bacterial species present in the sample by searching for the DNA code specific to Lyme or other bacteria, explained Dr. David Engelthaler, Director of Programs and Operations at TGen North, and Director of the Public Health and Translational Genomics Center at the Pathogen and Microbiome Institute. “LymeSeq has the potential to transform emergency rooms and doctor’s offices world wide, said Holly Ahern, MS, MT (ASCP) and SUNY Adirondack associate professor of microbiology, and a member of the leadership team at Focus on Lyme. Dr. Richard Horowitz, author of "How Can I Get Better? An Action Plan for Treating Resistant Lyme and Chronic Disease,” said, “more than ever, we need an accurate test” referencing the National Science Foundation’s identification of Lyme disease as an emerging pandemic threat, siting the current “problematic two-tiered testing scheme,” for which LymeSeq shows promise of being “superior in every way.” With exciting early signs of high accuracy, the next step is to advance the test into human trials. Crawford’s team of volunteers has raised more than $301,730 towards a goal of $500,000 to bring the test to market. BHHS Legacy Foundation recently stepped forward with an additional $100,000 in grant funding. “With the development of any new medical advancement, the steps are long, arduous and expensive. But we’ve come so far in such a short period of time, we need your help to get us to the finish line,” Crawford said. “We are all volunteers. Every single penny we raise goes towards the research, we keep nothing back.” For more information visit www.focusonlyme.org. To donate, visit: www.focusonlyme.org/donate.


PHOENIX, Feb. 28, 2017 (GLOBE NEWSWIRE) -- A new test for Lyme Disease may prove to be the most accurate tool available for the difficult-to-diagnose disease, giving hope to thousands of undiagnosed and misdiagnosed patients, if funding can be found to move it through clinical study to production. The test, called LymeSeq™ is poised to transform the speed and precision of diagnosis over current tests. This test will detect multiple strains of Lyme bacteria, plus all major co-infections and non-Lyme causes of disease like Influenza and Staph. LymeSeq, developed by research scientists at Translational Genomics Research Institute (TGen), has been funded by Focus On Lyme. The test may represent a breakthrough in diagnosis and testing for Lyme disease, which are currently about 50 percent accurate. After five years shuttling her daughter specialists across the country and intense antibiotic treatments to battle this disease, Focus On Lyme Executive Director Tammy Crawford got in touch with TGen. Knowing the institute’s experience using genetic sequencing to identify pathogens like tuberculosis and E. coli, Crawford asked if TGen could do the same for Lyme disease and when they said yes, she personally funded the initial research.  The researchers are led by Dr. Paul Keim, the Executive Director of the Pathogen and Microbiome Institute and the Cowden Endowed Chair of Microbiology at Northern Arizona University (NAU), as well as Director of the Pathogen Genomics Division TGen North in Flagstaff, Ariz. Dr. Keim is an internationally recognized expert in DNA-based research methods, a fellow of the American Academy of Microbiology, and a fellow of the American Association for the Advancement of Science. LymeSeq works by targeting and amplifying specific regions of the Lyme bacteria’s DNA as well as specific genes in related bacteria. That amplified DNA gets sequenced, then researchers determine the bacterial species present in the sample by searching for the DNA code specific to Lyme or other bacteria, explained Dr. David Engelthaler, Director of Programs and Operations at TGen North, and Director of the Public Health and Translational Genomics Center at the Pathogen and Microbiome Institute. “LymeSeq has the potential to transform emergency rooms and doctor’s offices world wide, said Holly Ahern, MS, MT (ASCP) and SUNY Adirondack associate professor of microbiology, and a member of the leadership team at Focus on Lyme. Dr. Richard Horowitz, author of "How Can I Get Better? An Action Plan for Treating Resistant Lyme and Chronic Disease,” said, “more than ever, we need an accurate test” referencing the National Science Foundation’s identification of Lyme disease as an emerging pandemic threat, siting the current “problematic two-tiered testing scheme,” for which LymeSeq shows promise of being “superior in every way.” With exciting early signs of high accuracy, the next step is to advance the test into human trials. Crawford’s team of volunteers has raised more than $301,730 towards a goal of $500,000 to bring the test to market. BHHS Legacy Foundation recently stepped forward with an additional $100,000 in grant funding. “With the development of any new medical advancement, the steps are long, arduous and expensive. But we’ve come so far in such a short period of time, we need your help to get us to the finish line,” Crawford said. “We are all volunteers. Every single penny we raise goes towards the research, we keep nothing back.” For more information visit www.focusonlyme.org. To donate, visit: www.focusonlyme.org/donate.


PHOENIX, Feb. 28, 2017 (GLOBE NEWSWIRE) -- A new test for Lyme Disease may prove to be the most accurate tool available for the difficult-to-diagnose disease, giving hope to thousands of undiagnosed and misdiagnosed patients, if funding can be found to move it through clinical study to production. The test, called LymeSeq™ is poised to transform the speed and precision of diagnosis over current tests. This test will detect multiple strains of Lyme bacteria, plus all major co-infections and non-Lyme causes of disease like Influenza and Staph. LymeSeq, developed by research scientists at Translational Genomics Research Institute (TGen), has been funded by Focus On Lyme. The test may represent a breakthrough in diagnosis and testing for Lyme disease, which are currently about 50 percent accurate. After five years shuttling her daughter specialists across the country and intense antibiotic treatments to battle this disease, Focus On Lyme Executive Director Tammy Crawford got in touch with TGen. Knowing the institute’s experience using genetic sequencing to identify pathogens like tuberculosis and E. coli, Crawford asked if TGen could do the same for Lyme disease and when they said yes, she personally funded the initial research.  The researchers are led by Dr. Paul Keim, the Executive Director of the Pathogen and Microbiome Institute and the Cowden Endowed Chair of Microbiology at Northern Arizona University (NAU), as well as Director of the Pathogen Genomics Division TGen North in Flagstaff, Ariz. Dr. Keim is an internationally recognized expert in DNA-based research methods, a fellow of the American Academy of Microbiology, and a fellow of the American Association for the Advancement of Science. LymeSeq works by targeting and amplifying specific regions of the Lyme bacteria’s DNA as well as specific genes in related bacteria. That amplified DNA gets sequenced, then researchers determine the bacterial species present in the sample by searching for the DNA code specific to Lyme or other bacteria, explained Dr. David Engelthaler, Director of Programs and Operations at TGen North, and Director of the Public Health and Translational Genomics Center at the Pathogen and Microbiome Institute. “LymeSeq has the potential to transform emergency rooms and doctor’s offices world wide, said Holly Ahern, MS, MT (ASCP) and SUNY Adirondack associate professor of microbiology, and a member of the leadership team at Focus on Lyme. Dr. Richard Horowitz, author of "How Can I Get Better? An Action Plan for Treating Resistant Lyme and Chronic Disease,” said, “more than ever, we need an accurate test” referencing the National Science Foundation’s identification of Lyme disease as an emerging pandemic threat, siting the current “problematic two-tiered testing scheme,” for which LymeSeq shows promise of being “superior in every way.” With exciting early signs of high accuracy, the next step is to advance the test into human trials. Crawford’s team of volunteers has raised more than $301,730 towards a goal of $500,000 to bring the test to market. BHHS Legacy Foundation recently stepped forward with an additional $100,000 in grant funding. “With the development of any new medical advancement, the steps are long, arduous and expensive. But we’ve come so far in such a short period of time, we need your help to get us to the finish line,” Crawford said. “We are all volunteers. Every single penny we raise goes towards the research, we keep nothing back.” For more information visit www.focusonlyme.org. To donate, visit: www.focusonlyme.org/donate.


RAPID CITY, S.D., Feb. 01, 2017 (GLOBE NEWSWIRE) -- National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University, a regionally accredited, proprietary, multi-campus institution of higher learning, today announced that on January 28, 2017, the Company’s Board of Directors declared a cash dividend in the amount of $0.045 per share on all shares of the Company’s common stock outstanding and of record as of the close of business on March 31, 2017, to be paid on or about April 7, 2017. The Company operates on a May 31st fiscal year. National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-campus institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations throughout the United States. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.


News Article | November 16, 2016
Site: www.prnewswire.com

DALLAS, Nov. 16, 2016 /PRNewswire-USNewswire/ -- National American University announced Tuesday that it has entered into a license agreement with RefactorU to utilize RefactorU's curriculum in an NAU intensive 10-week coding bootcamp to be offered at NAU's Lewisville campus located near Da...


RAPID CITY, S.D., Dec. 21, 2016 (GLOBE NEWSWIRE) -- National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University, a regionally accredited, proprietary, multi-campus institution of higher learning, today announced that it intends to release financial results for its fiscal 2017 second quarter ended November 30, 2016, after the closing of the stock market on January 4, 2017. The Company will then discuss those results in a conference call on Thursday, January 5, 2017, at 11:00 a.m. ET. Accompanying Slide Presentation and Webcast The Company will also have an accompanying slide presentation available in PDF format at the “Investor Relations” section of the NAU website at www.national.edu. The presentation will be made available 30 minutes prior to the conference call.  In addition, the call will be simultaneously webcast over the Internet via the “Investor Relations” section of the NAU website or by clicking on the conference call link: http://national.equisolvewebcast.com/q2-2017. The webcast will be archived and accessible for approximately 30 days. About National American University Holdings, Inc. National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-campus institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations throughout the central United States. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.


RAPID CITY, S.D., Dec. 21, 2016 (GLOBE NEWSWIRE) -- National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University, a regionally accredited, proprietary, multi-campus institution of higher learning, today announced that it intends to release financial results for its fiscal 2017 second quarter ended November 30, 2016, after the closing of the stock market on January 4, 2017. The Company will then discuss those results in a conference call on Thursday, January 5, 2017, at 11:00 a.m. ET. Accompanying Slide Presentation and Webcast The Company will also have an accompanying slide presentation available in PDF format at the “Investor Relations” section of the NAU website at www.national.edu. The presentation will be made available 30 minutes prior to the conference call.  In addition, the call will be simultaneously webcast over the Internet via the “Investor Relations” section of the NAU website or by clicking on the conference call link: http://national.equisolvewebcast.com/q2-2017. The webcast will be archived and accessible for approximately 30 days. About National American University Holdings, Inc. National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-campus institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations throughout the central United States. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.


News Article | September 28, 2016
Site: globenewswire.com

Company to host conference call on September 29, 2016, at 11:00 a.m. ET RAPID CITY, S.D., Sept. 28, 2016 (GLOBE NEWSWIRE) -- National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University (“NAU” or the “University”), a regionally accredited, proprietary, multi-campus institution of higher learning, today reported unaudited financial results for its fiscal 2017 first quarter ended August 31, 2016. Ronald L. Shape, Ed.D., President and Chief Executive Officer of the Company, stated, “We continue to remain focused on our various strategic initiatives for long-term growth and remain confident that our University is well positioned in a challenging environment. We are very pleased with the enrollment growth in our continuing education and workforce development programs, the growth in our graduate program, and the growth in our doctoral program.  However, the enrollment pressures in our undergraduate programs continued to be a factor for the summer term even though we have continued to adapt our operations appropriately while also placing greater emphasis on student engagement.   We are leveraging our operational flexibility and balance sheet to take advantage of opportunities within our market.  We continue to assist students impacted by schools that have closed or have announced that they are discontinuing enrollments.  Over the past year, NAU has worked to accept transfers from other institutions where students have been unable to complete their education.  We have worked closely with these individuals and new enrollees to highlight our academic programs and the commitment we have to our students’ success.  We have grown our continuing education enrollment, and are also expanding outside of the United States through accepting enrollments from students at Canadian institutions with which NAU partners.  We believe that the infrastructure we have built over the past year has begun to gain traction.  Overall, we are excited about the initiatives we continue to work on in FY 2017 and believe these opportunities will serve to strengthen the long-term foundation upon which NAU was built nearly 75 years ago.” Total NAU student enrollment for the summer 2017 term decreased 16.1% to 6,832 students from 8,139 during the prior summer term. Students enrolled in 57,800 credit hours compared to 70,621 credit hours during the prior summer term. The current average age of NAU’s students continues to be in the mid-30s, with those seeking undergraduate degrees remaining the highest portion of NAU’s student population. The following is a summary of student enrollment at August 31, 2016, and August 31, 2015, by degree level and by instructional delivery method: The Company, through its wholly owned subsidiary, operates in two business segments: the academic segment, which consists of NAU’s undergraduate, graduate, and doctoral education programs and contributes the primary portion of the Company’s revenue; and ownership in and development of multiple apartments and condominium complexes from which it derives sales and rental income. The real estate operations generated approximately 1.0% of the Company’s revenue for the quarter ended August 31, 2016. The Board of Directors declared a cash dividend in the amount of $0.045 per share on all shares of the Company’s common stock outstanding and of record as of the close of business on September 30, 2016, that will be paid on or about October 7, 2016. Management will discuss these results in a conference call (with accompanying presentation) on Thursday, September 29, 2016, at 11:00 a.m. ET. The Company will also have an accompanying slide presentation available in PDF format at the “Investor Relations” section of the NAU website at http://investors.national.edu. The presentation will be made available 30 minutes prior to the conference call.  In addition, the call will be simultaneously webcast over the Internet via the “Investor Relations” section of the NAU website or by clicking on the conference call link: http://national.equisolvewebcast.com/q1-2017. National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-campus institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations throughout the United States. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles. This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company's business. Statements made in this release, other than those concerning historical financial information, may be considered forward-looking statements, which speak only as of the date of this release and are based on current beliefs and expectations and involve a number of assumptions. These forward-looking statements include outlooks or expectations for earnings, revenue, expenses or other future financial or business performance, strategies or expectations, or the impact of legal or regulatory matters on business, results of operations or financial condition. Specifically, forward-looking statements may include statements relating to the future financial performance of the Company; the ability to continue to receive Title IV funds; the growth of the market for the Company’s services; expansion plans and opportunities; consolidation in the market for the Company’s services generally; and other statements preceded by, followed by or that include the words “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions. These forward-looking statements involve a number of known and unknown risks and uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by those forward-looking statements. Other factors that could cause the Company’s results to differ materially from those contained in its forward-looking statements are included under, among others, the heading “Risk Factors” in the Company’s Annual Report on Form 10-K, which the Company filed on August 5, 2016, and in its other filings with the Securities and Exchange Commission.  The Company assumes no obligation to update the information contained in this release. The following table provides a reconciliation of net income attributable to the Company to EBITDA/LBITDA: EBITDA consists of income attributable to the Company, less income from non-controlling interest, plus loss from non-controlling interest, minus interest income, plus interest expense (which is not related to any debt but to the accounting required for the capital lease), plus income taxes, plus depreciation and amortization. The Company uses EBITDA as a measure of operating performance. However, EBITDA is not a recognized measurement under U.S. generally accepted accounting principles, or GAAP, and when analyzing its operating performance, investors should use EBITDA in addition to, and not as an alternative for, income as determined in accordance with GAAP. Because not all companies use identical calculations, the Company’s presentation of EBITDA may not be comparable to similarly titled measures of other companies and is therefore limited as a comparative measure. Furthermore, as an analytical tool, EBITDA has additional limitations, including that (a) it is not intended to be a measure of free cash flow, as it does not consider certain cash requirements such as tax payments; (b) it does not reflect changes in, or cash requirements for, its working capital needs; and (c) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements, or future requirements for capital expenditures or contractual commitments. To compensate for these limitations, the Company evaluates its profitability by considering the economic effect of the excluded expense items independently as well as in connection with its analysis of cash flows from operations and through the use of other financial measures. The Company believes EBITDA is useful to an investor in evaluating its operating performance because it is widely used to measure a company’s operating performance without regard to certain non-cash expenses (such as depreciation and amortization) and expenses that are not reflective of its core operating results over time. The Company believes EBITDA presents a meaningful measure of corporate performance exclusive of its capital structure, the method by which assets were acquired and non-cash charges, and provides us with additional useful information to measure its performance on a consistent basis, particularly with respect to changes in performance from period to period.


News Article | April 8, 2016
Site: boingboing.net

Tom writes, "Scientists at Northern Arizona U. use a home-made machine to create 'exotic ices.' They're simulating the surface of Pluto to help explain data and pictures sent to Earth by the New Horizons spacecraft." MIT planetary science grad student Alissa Earle is using New Horizons and ice-lab data to study the boundaries of Pluto’s now-famous “heart” feature. The outskirts of the heart show signs of pitted ice and also of warmer ice rising to the surface, like blobs in a lava lamp. “This is just one of the regions where results from the NAU ice lab can really help us better understand what is going on... The work done in the lab helps us better understand how these substances behave at Pluto temperatures and pressures, which in turn helps us understand what we are seeing in the images being sent back by New Horizons.” And there’s plenty yet to understand, says Lowell astronomer Will Grundy, who as co-investigator of NASA’s New Horizons team had input into designing the mission. Scientists have known the nature of Pluto’s composition for decades, but New Horizons showed how the stuff on the little world’s surface interacts to build mountains and dig valleys. “[It’s] wild speculation until you see it laid out on a scale of tens of kilometers,” Grundy says.

Loading NAU collaborators
Loading NAU collaborators